our
science
What makes Entheos unique is that it has both a rapidly advancing, differentiated lead psychedelic asset (ET-01) with best-in-class potential and access to an AI-powered drug discovery platform through an exclusive Strategic Alliance with MGH. This phenotypic discovery engine leverages high-throughput, humanized neuroplasticity assays to advance a robust portfolio of novel, nonscheduled neuroplastogens derived from 50+ botanicals. These entheogenic botanicals, with long histories of human use, have been overlooked by Western science and competitors.
There are multiple documented plant varieties with strong, unique neuroplasticity enhancing properties.
ET-01 is a synthetic derivate of a natural product, that was selected based on safety, tolerability, user-experience profile, and potent 5HT2A receptor agonism. ET-01 is being developed with a novel formulation and delivery method that we believe will generate an optimal target product profile.
We are investigating the medicinal potential of underexplored botanicals from indigenous cultures that have remained enigmatic in terms of active principles and underlying targets and mechanisms.